Structure, heterogeneity and developability assessment of therapeutic antibodies
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - MAbs, 2019 - Taylor & Francis
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
Structure, heterogeneity and developability assessment of therapeutic antibodies.
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - Mabs, 2018 - europepmc.org
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
Structure, heterogeneity and developability assessment of therapeutic antibodies
Y Xu, D Wang, B Mason, T Rossomando, N Li… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
Structure, heterogeneity and developability assessment of therapeutic antibodies
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - mAbs, 2018 - hero.epa.gov
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
[HTML][HTML] Structure, heterogeneity and developability assessment of therapeutic antibodies
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - mAbs, 2019 - ncbi.nlm.nih.gov
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
[引用][C] Structure, heterogeneity and developability assessment of therapeutic antibodies
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - mAbs, 2018 - cir.nii.ac.jp
Structure, heterogeneity and developability assessment of therapeutic antibodies | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[PDF][PDF] Structure, heterogeneity and developability assessment of therapeutic antibodies
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - 2018 - researchgate.net
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
Structure, heterogeneity and developability assessment of therapeutic antibodies.
Y Xu, D Wang, B Mason, T Rossomando, N Li, D Liu… - Mabs, 2018 - europepmc.org
Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …